Newsroom October 9, 2026 Affinia Therapeutics’ AFTX-201 and UPBEAT™ Clinical Trial in BAG3 DCM Featured at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026 View More July 22, 2026 FDA Grants Orphan Drug Designation to Affinia Therapeutics’ AFTX-201 for the Treatment of BAG3-Associated Dilated Cardiomyopathy (DCM) View More May 14, 2026 Affinia Therapeutics Presents AFTX-201 Data and UPBEAT© Clinical Trial Design for BAG3-Associated Dilated Cardiomyopathy, Alongside Advances in BBB-Penetrant AAV Capsids and Proprietary Manufacturing, at the 29th ASGCT 2026 Annual Meeting View More April 28, 2026 Affinia Therapeutics to Present AFTX-201 for BAG3-Associated Dilated Cardiomyopathy (DCM) and Highlight Proprietary Capsid Engineering and Manufacturing Data at the American Society of Gene & Cell Therapy 2026 Annual Meeting View More April 6, 2026 Affinia Therapeutics Receives Approval from Health Canada to Initiate the UPBEAT© Trial, a Phase 1/2 Clinical Trial to Investigate AFTX-201 as a Treatment for BAG3-Associated Dilated Cardiomyopathy (DCM) View More March 4, 2026 Affinia Therapeutics Granted FDA Fast Track Designation for AFTX-201 as a Treatment for People Living with BAG3-Associated Dilated Cardiomyopathy (DCM) View More
